For instance, the identification of driver mutations (eg, EGFR T790M in NSCLC) can guide genotype-directed targeted therapy, whereas the identification of resistance mutations (eg, EGFR C797S mutation in NSCLC) can prevent futile treatments. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.